Group 1 - Cronos Group Inc. (NASDAQ: CRON) stock price increased by 15% on news that President Trump’s administration will consider rescheduling cannabis in the coming weeks [1] - The announcement has implications for Canadian cannabis licensed producers (LPs) and U.S. cannabis Multi-State Operators [1] Group 2 - The article is part of a monthly report on the cannabis industry, highlighting the author's expertise in technical stock analysis, option strategies, small cap strategies, and emerging markets [1]

智通财经APP获悉，周一，大麻概念股飙升，Canopy Growth(CGC.US)、Tilray Brands(TLRY.US)大涨近 20%，极光大麻(ACB.US)涨近13%，Cronos Group(CRON.US)涨近12%。消息面上，《华尔街日报》报 道特朗普正考虑将大麻重新归类为危险性较低药物。 ...

Cronos Group (CRON) Q2 2025 Earnings Call August 07, 2025 08:30 AM ET Speaker0Good morning. My name is Steven, and I will be your conference operator today. I would like to welcome everyone to Cronos Group's twenty twenty five Second Quarter Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Harrison Aaron, Senior Director, Investor Relations and Corporate Development.Please go ahead.Speaker1Thank you, Steven, and thank you for joining us today to r ...

Industry-leading balance sheet with $834 million in total cash and cash equivalents and short-term investments TORONTO, August 7, 2025 - Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company"), today announced its 2025 second quarter business results. "Cronos delivered another quarter of strong performance, highlighted by record sales from Cronos Israel and continued momentum in international markets. Our strength abroad has been instrumental in driving meaningful margin improvement, unders ...

Net revenue in Q2 2025 increased by 21% year-over-year PEACE NATURALS® retained its position as the number one cannabis brand in Israel1 Highest-ever international and Israel revenue, fueled by strong global demand Industry-leading balance sheet with $834 million in total cash and cash equivalents and short-term investments TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announced its 2025 second quarter business results. "Cronos del ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-38403 __________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or CRONOS GROUP INC. (Exact name of registrant as specified in its charter) ________________________ ...

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) will hold its 2025 second quarter earnings conference call on Thursday, August 7, 2025 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presenta ...

Industry Overview - The Canadian cannabis market is gaining investor attention as the U.S. cannabis industry continues to grow rapidly, with legal cannabis sales projected to reach nearly $39 billion in 2024 and potentially exceed $44 billion in 2025 [1] - Despite the growth, federal legalization in the U.S. remains stalled, but several states are advancing their own reform efforts, which is attracting interest in Canadian companies with U.S. exposure [1] Company Highlights - **Tilray Brands Inc. (TLRY)**: - Tilray has expanded significantly in the U.S., owning over 150 dispensaries in key markets like California and Michigan, and has diversified into the wellness and THC-infused beverage sectors [4][7] - The company reported a 13% increase in net revenue to $200 million, with its cannabis segment generating $61 million at a 40% gross margin, and a 132% year-over-year growth in the beverage segment [7] - Although Tilray posted a net loss, it narrowed that loss and achieved an adjusted EBITDA of $9 million, indicating improving fundamentals [7] - **Canopy Growth Corporation (CGC)**: - Canopy operates approximately 120 dispensaries in the U.S. and owns the vaporizer company Storz & Bickel, focusing on both recreational and medical markets [8][10] - The latest quarterly report showed net revenue of around C$66 million, a slight decrease from the previous year, but gross profit rose over 65% to achieve a 35% gross margin [10] - Canopy has cut its total debt by nearly 50% over the fiscal year, reflecting a strong focus on long-term sustainability and operational efficiency [10] - **Cronos Group Inc. (CRON)**: - Cronos has a growing presence in the U.S. with distribution deals supplying products to around 80 dispensaries, focusing on cannabinoid innovation [11][13] - The company reported net revenue of over $32 million, reflecting year-over-year growth, and gross profit rose to $13.7 million due to better cost management [13] - Cronos is investing in research and development to position itself for long-term success in the competitive U.S. market [13] Strategic Insights - The three Canadian cannabis companies—Tilray, Canopy Growth, and Cronos—are strategically expanding their U.S. footprint and improving financial health, making them key players to watch as U.S. legalization discussions continue [14]

Core Viewpoint - High Tide Inc. has secured a $30 million convertible debt loan from a subsidiary of Cronos Group to fund future acquisitions and expand its cannabis retail operations in Canada, aiming to grow its store network beyond 300 locations [1][2][3]. Group 1: Loan Agreement Details - The Junior Secured Loan has a principal amount of $30 million, secured by a third priority lien on certain assets of High Tide, and bears an interest rate of 4% per annum [4]. - The loan has a 5-year term and can be repaid at any time without penalty, with the option for Cronos to convert the loan into common shares at a price of $4.20 per share [4]. - Cronos also received a warrant to purchase up to 3,836,317 common shares at an exercise price of $3.91 per share, representing a 25% premium to the 30-day volume weighted average price [5]. Group 2: Company Growth and Strategy - High Tide aims to utilize the working capital from the loan to enhance its business operations and expand its retail presence, reinforcing its position as a key player in the legal cannabis ecosystem [2][3]. - The company has been recognized as one of Canada's Top Growing Companies and ranked number one in the retail category on the Financial Times list of Americas' Fastest Growing Companies for 2023 [11]. - High Tide operates the largest cannabis retail chain in Canada, Canna Cabana, with 202 locations and continues to innovate in retail technology and consumer products [7][8]. Group 3: Industry Context - The investment from Cronos reflects a belief in the importance of a competitive retail environment that benefits producers, retailers, and consumers alike [3]. - High Tide's integrated operations across various components of cannabis, including retail, consumption accessories, and CBD, position it well within the growing cannabis market [7][10].

Core Insights - Cronos Group Inc. is expanding its distribution of the PEACE NATURALS medical cannabis brand in Switzerland through a partnership with Dascoli Pharma AG, a Swiss company specializing in medical cannabis supply and distribution [1][2] - The partnership aims to provide high-quality medical cannabis to Swiss patients and aligns with Cronos' mission to offer borderless cannabis products in European medical markets [2] - Cronos will supply PEACE NATURALS-branded cannabis flower to Dascoli for distribution across its established medical network in Switzerland, marking a significant step in Cronos' international growth strategy [2] Company Overview - Cronos Group Inc. is a global cannabinoid company focused on advancing cannabis research, technology, and product development, with a diverse international brand portfolio including Spinach, PEACE NATURALS, and Lord Jones [4] - The company is committed to building disruptive intellectual property and enhancing the consumer experience through its iconic brand portfolio [4] Partner Overview - Dascoli Pharma AG is a Swiss pharmaceutical firm that focuses on medical cannabis manufacturing and distribution across wholesale and retail channels, providing compliant cannabinoid therapies to patients, pharmacies, and clinics [5] - Dascoli is recognized as a leading cannabinoid retailer in Switzerland, offering next-day home delivery services for patients [5] Product Availability - PEACE NATURALS medical cannabis products are now available in multiple countries, including Australia, Canada, Germany, Israel, Malta, Switzerland, and the UK [3]